CN Mobile Logo

Search form


Lung Cancer

Using Immune Checkpoint Inhibitors in Lung Cancer

Immune checkpoint inhibitors have changed the treatment paradigm for patients with lung cancer, bringing about the most promising outcomes we have seen in a long time.

Lung Cancer

The LUX-Lung 7 trial found no significant differences between afatinib and gefitinib for patients with EGFR mutation–positive stage IIIb/IV NSCLC.

A better delineation of the relationships between lung cancer, COPD, and emphysema may lead to significant improvements in the effectiveness of lung cancer screening programs, and to reductions in the morbidity and mortality associated with these deadly diseases.

The addition of bevacizumab to a first-line regimen of cisplatin and etoposide improved progression-free survival in patients with extensive-disease small-cell lung cancer.

The oral ALK inhibitor ceritinib provided a significant improvement in progression-free survival over platinum-based chemotherapy in patients with previously untreated ALK-rearranged non-small-cell lung cancer.

A delay in initiation of adjuvant chemotherapy following resection for non–small-cell lung cancer was not associated with any increase in mortality.

A database analysis shows significant shifts in treatment patterns for elderly patients diagnosed with advanced-stage non–small-cell lung cancer, along with a modest gain in survival since 2000.

In this interview we discuss the use of liquid biopsies in lung cancer, the pros and cons compared with tissue biopsies, and how they can be used to help make treatment decisions.


Subscribe to Lung Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.